Continuous venous infusion of vinblastine in metastatic breast cancer

Paolo Pronzalo, Paola Queirolo, Maria Giuseppina Vidili, Domenico Amoroso, Gianfdippo Berlelli, Mario Roberto Sertoli, Riccardo Rosso

Research output: Contribution to journalArticlepeer-review


In 19 patients with advanced pretreated breast cancer, vinblastine was administered by continuous venous infusion (2 mg/m2/24 h for 120 h every 3 weeks), using a totally implanted venous access and a portable pump. A total of 55 courses were given. Five objective responses were observed. Drug-related toxicity consisted mainly of leukopenia (4 patients), fever (4 patients) and nausea and vomiting (3 patients). Catheter-related toxicity was observed in 4 patients (21%) and consisted of infection of the skin pocket in 1 patient and dislodging of the needle with drug extravasation in 3 patients.

Original languageEnglish
Pages (from-to)146-149
Number of pages4
Issue number2
Publication statusPublished - 1991


  • Breast cancer
  • Continuous-infusion chemotherapy
  • Vinblastine

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Continuous venous infusion of vinblastine in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this